Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alterity Therapeutics Ltd (ATHE)
NASDAQ:ATHE
Holding ATHE?
Track your performance easily
ATHE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.01 - $5.41
Previous Close$1.2
Volume21.52K
Average Volume (3M)33.95K
Market Cap
$10.80M
Enterprise Value$353.93K
Total Cash (Recent Filing)AU$15.77M
Total Debt (Recent Filing)AU$210.38K
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Feb 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding4,066,496
10 Day Avg. Volume8,381
30 Day Avg. Volume33,945
Standard Deviation0.21
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.21
Price to Sales (P/S)1.97
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Alterity Therapeutics News
PremiumCompany Announcements
Alterity Therapeutics Options Expire Unexercised
PremiumCompany Announcements
Alterity Therapeutics Options Expire Unexercised
PremiumPress Releases
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
Ownership Overview
0.00%
Insiders
0.01% Mutual Funds
0.07% Other Institutional Investors
99.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ATHE FAQ
What was Alterity Therapeutics Ltd’s price range in the past 12 months?
Alterity Therapeutics Ltd lowest stock price was $1.01 and its highest was $5.41 in the past 12 months.
What is Alterity Therapeutics Ltd’s market cap?
Currently, no data Available
When is Alterity Therapeutics Ltd’s upcoming earnings report date?
Alterity Therapeutics Ltd’s upcoming earnings report date is Feb 27, 2025 which is in 161 days.
How were Alterity Therapeutics Ltd’s earnings last quarter?
Alterity Therapeutics Ltd released its earnings results on Feb 28, 2024. The company reported -$0.515 earnings per share for the quarter, missing the consensus estimate of -$0.107 by -$0.408.
Is Alterity Therapeutics Ltd overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Overvalued.
Does Alterity Therapeutics Ltd pay dividends?
Alterity Therapeutics Ltd does not currently pay dividends.
What is Alterity Therapeutics Ltd’s EPS estimate?
Alterity Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd have?
Alterity Therapeutics Ltd has 8,867,227 shares outstanding.
What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?
Alterity Therapeutics Ltd reported an EPS of -$0.515 in its last earnings report, missing expectations of -$0.107. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?
Currently, no hedge funds are holding shares in ATHE
---
Alterity Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.57%
12-Months-Change
Fundamentals
Return on Equity
-102.86%
Trailing 12-Months
Asset Growth
-29.40%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd
Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
---
Technical Analysis
Apellis Pharmaceuticals
―
SELLAS Life Sciences Group
―
Cellectar Biosciences
―
Moleculin Biotech
―
---